 Innovative Ketamine clinical trial ranked in the 94th percentile by the CIHR peer review committee Suicidality remains second-leading cause of death among youth and young adults, and the 9th most common cause of death among Canadians TORONTO, July 28, 2021 PRNewswire - Braxia Scientific Corp. Braxia, or the Company, CSE: BRAX OTC: BRAXF FWB: 496, a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, congratulates Chief Executive Officer Dr. Roger McIntyre and Chief Medical and Scientific Officer Dr. Josh Rosenblat for receiving 918,000 in funding from the Canadian Institutes of Health Research CIHR, the Government of Canadas federal funding agency for health research. The funding will be used to evaluate the effectiveness of intravenous ketamine, in combination with internet-based cognitive behavioural therapy iCBT, to rapidly reduce suicidality in persons with depression, when compared to iCBT alone. 